BSE Live
Mar 11, 16:01Prev. Close
243.85
Open Price
243.85
Bid Price (Qty.)
242.65 (22)
Offer Price (Qty.)
247.95 (11)
NSE Live
Mar 11, 15:53Prev. Close
243.45
Open Price
248.80
Bid Price (Qty.)
245.10 (50)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Wanbury (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 9.32 | 9.29 | -3.18 | 25.29 | -5.04 | |
| Diluted EPS (Rs.) | 8.98 | 9.18 | -3.18 | 25.21 | -5.04 | |
| Cash EPS (Rs.) | 13.38 | 13.26 | 0.61 | 28.45 | -1.14 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 18.09 | 8.53 | -2.22 | 0.67 | -52.23 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 18.09 | 8.53 | -2.22 | 0.67 | -52.23 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 182.94 | 175.80 | 152.77 | 156.49 | 156.91 | |
| PBDIT/Share (Rs.) | 24.35 | 22.29 | 7.36 | 11.27 | 8.16 | |
| PBIT/Share (Rs.) | 20.29 | 18.31 | 3.58 | 7.77 | 4.27 | |
| PBT/Share (Rs.) | 9.02 | 9.40 | -3.15 | 24.84 | -4.96 | |
| Net Profit/Share (Rs.) | 9.32 | 9.28 | -3.18 | 24.94 | -5.04 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 13.31 | 12.67 | 4.82 | 7.20 | 5.20 | |
| PBIT Margin (%) | 11.09 | 10.41 | 2.34 | 4.96 | 2.71 | |
| PBT Margin (%) | 4.92 | 5.34 | -2.05 | 15.87 | -3.16 | |
| Net Profit Margin (%) | 5.09 | 5.28 | -2.08 | 15.93 | -3.21 | |
| Return on Networth / Equity (%) | 51.50 | 108.79 | 0.00 | 3,724.18 | 0.00 | |
| Return on Capital Employed (%) | 27.78 | 46.34 | 129.25 | 138.00 | -26.28 | |
| Return on Assets (%) | 7.37 | 8.85 | -3.43 | 23.21 | -4.38 | |
| Total Debt/Equity (X) | 2.92 | 3.94 | -8.84 | 30.64 | -0.68 | |
| Asset Turnover Ratio (%) | 1.58 | 1.78 | 1.53 | 1.60 | 1.39 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.11 | 0.74 | 0.42 | 0.52 | 0.30 | |
| Quick Ratio (X) | 0.89 | 0.58 | 0.34 | 0.37 | 0.23 | |
| Inventory Turnover Ratio (X) | 16.27 | 9.97 | 7.18 | 8.18 | 11.52 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 929.36 | 581.65 | 182.30 | 319.41 | 284.25 | |
| EV/Net Operating Revenue (X) | 1.55 | 1.01 | 0.36 | 0.62 | 0.72 | |
| EV/EBITDA (X) | 11.64 | 7.97 | 7.57 | 8.67 | 13.92 | |
| MarketCap/Net Operating Revenue (X) | 1.28 | 0.83 | 0.24 | 0.54 | 0.53 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 12.97 | 17.09 | -16.82 | 127.06 | -1.59 | |
| Price/Net Operating Revenue | 1.28 | 0.83 | 0.24 | 0.54 | 0.53 | |
| Earnings Yield | 0.04 | 0.06 | -0.09 | 0.29 | -0.06 |
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities